Lloyd E. Damon, MD

Olivet College, Olivet, Michigan, B.A., 1978, Chemistry/Biology
University of Michigan Medical School, Ann Arbor, M.D., 1982, Medicine
University of California San Francisco, Residency, 1985, Internal Medicine
University of California San Francisco, Fellowship, 1988, Hematology/Oncology

• 1976-1978
  Instructor, Organic Chemistry Laboratory, Olivet College
• 1988-1989
  Clinical Instructor of Medicine, Univ. California, San Francisco
• 1989-1995
  Assistant Clinical Professor of Medicine, Univ. California, San Francisco
• 1996-2000
  Associate Clinical Professor of Medicine, Univ. California, San Francisco
• 2000-present
  Clinical Professor of Medicine, Univ. California, San Francisco
• 1989-Present
  Director, Apheresis and Stem cell Collection Unit, University of California, San Francisco

• 1985
  American Cancer Society Clinical Fellowship Award
• 2001, 2003
  Faculty teaching award, Division of Hematology-Oncology
• 2003
  Exceptional Physician Award, UCSF Medical Center
• 2007
  "Master Clinician" Award, UCSF Department of Medicine

• Damon LE (1982) Effect of relocation on the elderly. Am Fam Phys 26: 144-148.
• Damon LE, Cadman EC (1986) Recent advances in combination chemotherapy. Cancer Invest 4:421-444.
• Damon L, Adams M, Stricker R, Ries C (1987) Intracranial bleeding during treatment with hydroxyl ethyl starch. N Engl J Med 317:964-965 (letter).
• Damon LE, Cadman EC (1988) Metabolic basis for combination chemotherapy. Pharmacol Ther 38:73-127.
• Rochlitz CR, Damon LE, Russi MB, Geddes A, Cadman, EC (1988) Cytotoxicity of ketoconazole in malignant cell lines. Cancer Chemother Pharmacol 21:319-322.
• Damon LE, Cadman EC, Benz C (1989) Enhancement of 5-fluorouracil antitumor effect by the prior administration of methotrexate. Pharmacol Ther 43:155-185.
• Damon LE, Mass R, Linker CA (1989) The association between high-dose cytosine arabinoside neurotoxicity and renal insufficiency. J Clin Oncol 7:1563-1568.
• Damon LE, Christensen S, Rochlitz CR, Cadman EC (1989) Sequence-dependent synergistic cytotoxicity between etoposide and fluoropyrimidines. Anticancer Res 9:1761-1768.
• Damon LE, Plunkett W, and Linker CA (1991) Plasma and cerebrospinal fluid pharmacokinetics of 1-β-D-arabinofuranosylcytosine and 1-β-D-arabinofuranosyluracil following the repeated intravenous administration of high and intermediate dose 1-β-D-arabinofuranosylcytosine. Cancer Res 51:4141-4145.
• Damon LE (1992) Anemias of chronic disease in the aged: diagnosis and treatment. Geriatrics 47:47-57.
• Damon LE, Plunkett W, and Linker CA (1992) Plasma and cerebrospinal fluid pharmacokinetics of 1-β-D-arabinofuranosylcytosine and 1-β-D-arabinofuranosyluracil following the repeated intravenous administration of high-and -intermediate-dose 1-β-D-arabinofuranosylcytosine. Cancer Res. 52:3819-3820 (reply to letter to the editor).
• Thompson CE, Damon LE, Ries CA, and Linker CA (1992) Thrombotic microangiopathies in the 1980's: clinical features, response to treatment, and the impact of the HIV epidemic. Blood 80:1890-1895.
• Linker CA, Ries CA, Damon LE, Rugo HS, and Wolf JL, (1993). Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood. 81:311-318.
• Galli FC, Damon LE, Tomlanovich SJ, Keith F, Chatterjee K, and DeMarco T (1993). Cyclosporine induced hemolytic uremic syndrome in a heart transplant recipient. J Heart Lung Transpl. 12:440-444.
• Small EJ, Venook AP, and Damon LE (1993). Gallium avid thymic hyperplasia in an adult following chemotherapy for Hodgkin's disease: a case report and review of the literature. Cancer 72:905-908.
• Linker CA, Damon LE, Ries CA, Rugo HS, Wolf JL (1993). Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update. Semin Oncol 20 (Suppl 4): 40-48.
• Damon LE, Rugo HS, Ries CA, Linker CA (1994). Post-remission cytopenias following intense induction chemotherapy for acute myeloid leukemia. Leukemia 8:535-541.
• Rugo HS, Damon LE, Ries CA, Wolf JL, Linker CA (1994). High-dose chemotherapy for peripheral stem cell procurement in leukemia, lymphoma and multiple myeloma. Progress Clin Biology Research 389: 505-11.
• Lipschutz JH, Miller T, Yen TSB, Vartannian RK, Graber ML, Damon LE, (1995). Unreliability of the abdominal fat pad biopsy in the evaluation of nephrosis: report of 3 consecutive cases. Am J Nephrol 15: 431-435.
• Damon LE, Rugo HS, Ries CA, Linker CA (1996). Delayed engraftment of 4-hydroperoxyclophosphamide-purged autologous bone marrow after induction treatment containing mitoxantrone for acute myelogenous leukemia. Bone Marrow Transpl 17:93-9.
• Terdiman JP, Linker CA, Ries CA, Damon LE, Rugo HS, Ostroff JW (1996). The role of endoscopic evaluation in patients with suspected intestinal graft-versus-host disease after allogeneic bone marrow transplantation. Endoscopy 28:680-5.
• Zander AR, Kruger W, Kroger N, Damon L, Konigmann M, Berdel WE, Gieseking F, Schafer-Eckart K, Mobus V, Frickhofen N, Wandt H, Illiger HJ, Metzner B, Kolbe K, Wormann B, Trumper L, Huber C, Hossfeld DK, Maass H, Jonat W, for the German GABG-4/EH-93-Study (1996). High dose mitoxantrone with thiotepa, cyclophosphamide and autologous stem cell rescue for high risk stage II and stage III breast cancer. Bone Marrow Transpl 18 (Suppl 1):S24-25.
• DeMarco T, Damon LE, Colombe B, Keith F, Chatterjee K, Garovoy M (1997). Successful immunomodulation with intravenous gammaglobulin and cyclophosphamide in an alloimmunized cardiac transplant recipient. J Heart Lung Transpl.16:360-5.
• Smith GA, Damon LE, Rugo HS, Ries CA, Linker CA (1997). High-dose Ara-C (HDAC) dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol 15:833-839.
• Damon LE (1997). Increasing survival in invasive breast cancer. Cancer Management Today 2:1-5.
• Feldman EJ, Seiter K, Damon L, Linker C, Rugo H, Ries C, Case DC Jr, Beer M, Ahmed T (1997). A randomized trial of high vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Leukemia 11: 485-489. Feldman EJ, Seiter K, Damon L, Linker C, Rugo H, Ries C, Case DC Jr, Beer M, Ahmed T (1997). A randomized trial of high vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia. Leukemia 11: 485-489.
• Linker CA, Ries CA, Damon LE, Rugo HS, and Wolf JL (1998). Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report. Bone Marrow Transpl 22:865-872.
• Damon LE, Wolf JL, Rugo HS, Gold E, Zander AR, Cassidy M, Cecchi G, Cohen N, Irwin D, Tracy M, Ries CA, and Linker CA (2000). High-dose chemotherapy (CTM) for breast cancer: improved results in patients with >10 involved axillary lymph nodes. Bone Marrow Transpl 26: 257-268.
• Linker CA, Ries CA, Damon LE, Rugo HS, Rubin A, Case D, Crilley P, Topolsky D, Brodsky I, Zamkoff K, and Wolf J (1999). Autologous stem cell transplantation for acute myeloid leukemia in first remission. Biol Blood Marrow Transpl 6: 50-57.
• Damon LE, Hu WH, Stockerl-Goldstein KE, Blume K, Wolf JL, Gold E, Cecchi GR, Irwin D, Glaspy J, Territo M, Miller W, Mason JR, and Linker CA (2000). High-dose chemotherapy and hematopoietic stem cell rescue for breast cancer: experience in California. Biol Blood Marrow Transpl 6:496-505.
• Bright R, Eisendrath S, Damon L (2001). A case of factitious aplastic anemia. Int J Psychiatry Med 31: 433-441.
• Linker CA, Damon LE, Ries CA, Navarro WA, Case D, Wolf JL (2002). Autologous stem cell transplantation for advanced acute myeloid leukemia. Bone Marrow Transpl 29: 297-301.
• Linker C, Damon L, Ries C, Navarro W (2002). Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol 20: 2464-2471.
• Damon L. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. Author update (2002), Classic Papers Current Comments 7: 245-251.
• Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, Grillo-Lopez A, Shuman M. (2003). Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 101:466-468.
• Gunn N, Damon L, Varosy P, Navarro W, Martin T, Ries C, Linker C (2003). High CD34 cell dose promotes faster platelet engraftment after autologous stem cell transplantation for acute myeloid leukemia. Biol Blood Marrow Transplant 10: 643-648.
• O'Donnell MR, Applebaum FR, Baer MR, Byrd JC, Coutre SE, Damon L, Devetten M, Erba HP, Estey E, Foran J, Maslak P, Millenson M, Moore JO, Przepiorka D, Saba HI, Shami P, Smith BD, Stone R, Tallman M (2003). Acute Myeloid leukemia. Clinical practice guidelines in oncology. J Natl Comprehensice Cancer Network 1; 520-539.
• Kroger N, Damon L, Zander AR, Wandt H, Derigs G, Ferrante P, Demirer T, Rosti G. (2003) Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients. Bone Marrow Transplant 32: 1153-1157.
• Damon L, Johnston LJ, Ries CA, Rugo HS, Case D, Ault K, Linker CA. (2004). Treatment of acute leukemia with idarubicin, etoposide and cytarabine (IDEA). A randomized study of etoposide schedule. Cancer Chemotherapy Pharmacol 53: 468-74.
• Somlo G, Frankel P, Chow W, Leong L, margolin K, Morgan R Jr, Shibata S, Chu P, Forman S, Lim D, Twardowski P, Weitzel J, Alvarnas, Kogut N, Schriber J, Fermin E, Yen Y, Damon L, Doroshow JH. (2004) Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy. J Clin Oncol 22: 1839-48.
• Beinart G, Damon L (2004) Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia. Am J Hematol 77: 331-335.
• Michaels MG, Kaufman C, Volberding PA, Gupta P, Switzer WM, Heneine W, Sandstrom P, Kaplan L, Swift P, Damon L, Ildstad ST. (2004) Baboon bone-marrow xenotransplant in a patient with advanced HIV disease: case report and 8-year follow-up. Transplantation 78: 1582-9.
• Muss HB, Von Roenn J, Damon L, Deangelis LM, Flaherty LE, Harai PM, Kelly K, Kosty MP, Loscalzo MJ, Mennel R, Mitchell BS, Mortimer JE, Muggia F, Perez EA, Pisters PW, Saltz L, Shapira L, Sparano J, American Society of Clinical Oncology. (2005) ACCO: ASCO core curriculum outline. J Clin Oncol 23: 2049-77.
• Chaudhary UB, Damon LE, Rugo HS, Linker CA, Navarro W, Small EJ. (2005) High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancer. Am J Clin Oncol 2: 130-7.
• Damon L, Rugo H, Tolaney S, Navarro W, Martin III T, Ries C, Case D, Ault K, Linker C. (2006) Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. Biol Blood Marrow Transplant 12: 316-24.
• Zelenetz AD, Advani RH, Buadi F, Cabanillas F, Caligiuri MA, Czuczman MS, Damon LE, Fayad L, Flinn IW, Forero A, Glenn MJ, Gockerman JP, Gordon Li, Harris NL, Hoppe RT, Kaminski MS, Lacasce AS, Nademanee A, Porcu P, Press O, Prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J. (2006) Non-Hodgkin's Lymphoma. J Natl Compr Canc Netw 4: 258-310.
• O'Donnell MR, Appelbaum FR, Baer MR, Byrd JC, Coutre SE, Damon LE, Erba HP, Estey E, Foran J, Lancet J, Maness LJ, Maslak PG, Millenson M, Moore JO, Przepiorka D, Shami P, Smith BD, Stone RM, Tallman MS. (2006) Acute myeloid leukemia clinical practice guidelines in oncology. J Natl Compr Canc Netw 4(1): 16-36.
• Mintz PD, Neff A, Mackenzie M, Goodnough LT, Hillyer C, Kessler C, McCrae K, Menitove JE, Skikne BS, Damon L, Lopez-Plaza I, Rouault C, Crookston KP, Benjamin RJ, George J, Lin JS, Corash L, Conlan MG. (2006) A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura. Transfusion 46(10):1693-704.
• Fitzgerald PA, Goldsby RE, Huberty JP, Price DC, Hawkins RA, Veatch JJ, Cruz FD, Jahan TM, Linker CA, Damon L, Matthay KK. (2006) Malignant pheochromocytoma and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci 1073: 465-490.
• Fix O, Damon LE, Bass NM. (2007) Amyloidosis localized to the liver. Clin Gastroenterol Hepatol. Feb; 5 (2): e7.
• Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, Issa S, Damon L, Prados M, McDermott M, O'brien J, Haqq C, Shuman M. (2007) Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 25: 1350-1356.
• Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Becker CH, Schulman H, Rubenstein JL. (2008) Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol. 26: 96-105.
• Zelenetz AD, Advani RH, Byrd JC, Czuczman MS, Damon LE, Duvic M, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kaminski MS, Kim YH, Lacasce AS, Nademanee A, Olsen EA, porcu P, Press O, prosnitz L, Smith MR, Sotomayor EM, Vose JM, Yahalom J, Yunus F. (2008) Non-Hodgkin's lymphoma. J Natl Compr Cancer Netw, 6: 356-421.
• Damon L, Damon LE, Gaensler K, Kaplan L, Martin T 3rd, Rubenstein J, Linker C. (2008) Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma. Bone Marrow Transplant, 42: 649-657.
• His ED, Jung SH, Lai R, Johnson JL, Cook JR, Jones D, Devos S, Cheson BD, Damon LE, Said J. (2008) Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia group B 59909 correlative science study. Leuk Lymphoma, 49: 2081-2090.
• O'Donnell MR, Applebaum FR, Coutre SE, Damon LE, Erba HP, Foran J, Lancet J, Maness LJ, Marcucci G, Maslak PG, Millenson M, Moore JO, Ravandi F, Schuening F, Shami P, Smith BD, Stome RM, Tallamn MS, Wang E, White FL. (2008) NCCN clinical preactice guidelines in oncology. Acute myeloid leukemia, version1:2009. J National Comprehensive Cancer Network, 6; 962-993.